Ask AI
IL-13 inhibitors for atopic dermatitis

CE / CME

Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: August 11, 2025

Expiration: August 10, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case: A 34-Yr-Old Female with Severe AD



  • A 34-yr-old female presents with severe AD

  • Current Presentation

    • Persistent symptoms: redness, itching, scaling

    • Medications: topical corticosteroids and emollients

    • AD has worsened over the past year with sleep disruption due to itching

    • Past medical history: noncontributory



  • Laboratory results

    • IgE: 2,450 IU/mL

    • Eosinophils: 9.2% (absolute: 750 cells/µL)

    • CRP: 3.2 mg/L

    • ESR: 28 mm/hr 



Based on the role of IL-13 in AD, which of the following best describes its pathophysiologic contributions to this patient's clinical manifestations?

2.

Which of the following biologic therapies would be the most appropriate choice for targeting IL-13 to improve a patient’s skin barrier function and reduce inflammation?

3.

Considering the patient’s clinical presentation, history, and lab findings, which of the following factors most strongly supports initiating an IL-13–targeting biologic therapy for her atopic dermatitis?